New COPD Candidates Could Get Hung Up On Safety Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.